Danvers, MA, USA, October 24, 2023
Cell Signaling Technology (CST), a life science discovery technology company and leading provider of antibodies, kits, and services, announced their partnership with The Michael J. Fox Foundation for Parkinson's Research (MJFF) today to identify and develop high-quality monoclonal antibodies for promising Parkinson’s disease (PD) targets. The availability of rigorously validated, reproducible, and readily accessible antibody reagents that target PD-relevant proteins remains a key barrier to therapeutic development for Parkinson’s patients. As part of the partnership, CST and MJFF scientists will collaborate closely to identify promising PD targets and develop relevant, highly validated reagents to accelerate Parkinson’s disease research.
Currently, an estimated 10 million people worldwide are living with PD, and this number is expected to double by 2040. There is an increasingly critical need for advanced research tools and reagents to help understand the underlying mechanisms of PD, to aid in analyzing everything from patient risk to disease progression and therapeutic response.
“As scientists, we are driven by an innate desire to advance our understanding of human disease,” said Roberto Polakiewicz, Chief Scientific Officer at CST. “With Parkinson’s disease, however, it’s also personal—many of us at CST have loved ones who experience this pervasive and debilitating neurological disorder. We are proud to partner with MJFF, combining our expertise to develop best-in-class antibody reagents and utilize the foundation’s cutting-edge insights into PD mechanisms of disease progression to identify and develop the research tools needed to bring us closer to a cure.”
CST offers an extensive portfolio of antibodies and assay kits to interrogate key PD-associated proteins, including DJ-1 (PARK7), LRRK2/dardarin, α/β-synuclein (SNCA), and PINK1. Working in collaboration with MJFF, novel targets will be chosen based on emerging areas of PD investigation to prioritize the development of new, highly validated antibody reagents that will drive research forward.
“We are excited to work with CST to identify and produce antibodies against critical PD targets to speed preclinical research,” said Nicole Polinski, PhD, Director of Research Programs, MJFF. “As novel insights into disease mechanisms are uncovered, the rapid development, validation, and distribution of high-caliber antibodies for important PD targets will enable cutting-edge research to transform how we diagnose, treat, and care for Parkinson’s patients. CST’s reputation for stringent antibody validation and trusted, reproducible results makes them an ideal partner for this important work.”
According to the CiteAb reagent database, over one-third of the top 100 most cited antibodies in peer-reviewed publications are from CST, more than any other antibody vendor. Across the industry, CST® antibodies are trusted for their sensitivity, specificity, and reproducible performance in approved assays, thanks to the company’s commitment to rigorous validation standards and a strong scientific foundation.
To learn more about the MJFF and CST partnership, stop by CST booth #1800 at the 53rd annual meeting of the Society for Neuroscience (SfN), Neuroscience 2023, to be held November 11-15.
Cell Signaling Technology (CST) is a different kind of life science company—one founded, owned, and run by active research scientists, with the highest standards of product and service quality, technological innovation, and scientific rigor. Founded in 1999 and headquartered in Danvers, Massachusetts, USA, CST employs over 600 people worldwide. We consistently provide fellow scientists around the globe with best-in-class products and services to fuel their quests for discovery. CST is a company of caring people driven by a devotion to facilitating good science—a company committed to doing the right thing for our customers, our communities, and our planet. cellsignal.com
For more information, visit www.michaeljfox.org.
CST Media and Press
Rebecca J. Reppucci, MBA
Cell Signaling Technology, Inc.
Senior Director, Global MarComm & Technology
Phone: 978-880-3334
email: [email protected]
